slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 77,431-77,460
Pages 3,679
Rows per page 30
Component
77,431-77,460 of 110,355
18
The chart shows a dip in 2021 followed by a recovery, with a guidance range for 2024-2025.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The chart includes a specific target box for 16-18% and a footnote regarding FY 2024 guidance.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
59
The slide uses a mix of metrics to demonstrate vertical integration and production footprint expansion.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations 1 hit
68
The slide uses brand imagery and color-coded blocks to present performance metrics.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
69
Hugo Boss | Investor Presentation Deck | 99 slidesHugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
70
The slide uses a consistent layout to compare performance across three distinct sales channels.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
74
The slide uses a three-column layout to explain the drivers of cash flow performance.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
75
The slide highlights a 35% increase in dividend per share and shows the payout ratio remaining within the 30-50% target band.Hugo Boss | Investor Presentation Deck | 99 slides · Hugo Boss
Conference presentation Investor relations Beat · Financials1 hit
25
The slide uses brand imagery and color-coded blocks to present financial growth metrics.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
26
The slide uses a map-based visual layout to categorize performance by region.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
27
The slide uses a three-column layout to compare performance metrics across different sales channels.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
31
The slide uses a three-column layout to present key financial performance indicators and their drivers.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
32
The slide highlights a 35% increase in dividend per share and shows the payout ratio remains within the 30-50% target range.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
03
The slide uses a three-column layout for strategic pillars followed by a bottom section highlighting clinical performance metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a structural diagram to map technical modifications to clinical outcomes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
15
The slide highlights NXC-201's 100% overall response rate and superior cardiac response compared to CAEL-101 and Birtamimab.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
19
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
The diagram shows a summation of two patient groups (prevalence and incidence-derived relapsed/refractory) to reach a total eligible patient count.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
The slide uses a molecular biology diagram to illustrate structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
30
Uses a before-and-after framing to illustrate market expansion potential.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit